BioLife Solutions Inc (NASDAQ:BLFS) VP Todd Berard sold 3,000 shares of BioLife Solutions stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $17.47, for a total value of $52,410.00. Following the completion of the sale, the vice president now directly owns 44,074 shares in the company, valued at approximately $769,972.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Todd Berard also recently made the following trade(s):
- On Wednesday, May 15th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The stock was sold at an average price of $16.96, for a total value of $50,880.00.
- On Monday, April 15th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.56, for a total value of $52,680.00.
Shares of BioLife Solutions stock traded down $0.03 on Thursday, reaching $17.57. The company had a trading volume of 25 shares, compared to its average volume of 144,815. The stock has a market cap of $330.88 million, a price-to-earnings ratio of 125.86 and a beta of 1.46. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.99 and a current ratio of 14.50. BioLife Solutions Inc has a 1 year low of $9.15 and a 1 year high of $26.35.
A number of research firms have issued reports on BLFS. BidaskClub downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Thursday, May 30th. Maxim Group set a $24.00 price objective on BioLife Solutions and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Zacks Investment Research raised BioLife Solutions from a “sell” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Wednesday, May 15th. Northland Securities reaffirmed a “buy” rating and issued a $18.00 price objective on shares of BioLife Solutions in a research note on Monday, May 13th. Finally, ValuEngine downgraded BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $17.80.
Several institutional investors have recently made changes to their positions in BLFS. FMR LLC purchased a new position in shares of BioLife Solutions during the first quarter worth $2,684,000. Marshall Wace LLP boosted its holdings in BioLife Solutions by 210.0% in the first quarter. Marshall Wace LLP now owns 30,278 shares of the medical equipment provider’s stock valued at $542,000 after purchasing an additional 20,512 shares during the period. Spears Abacus Advisors LLC purchased a new position in BioLife Solutions in the first quarter valued at $243,000. Granite Investment Partners LLC boosted its holdings in BioLife Solutions by 25.5% in the first quarter. Granite Investment Partners LLC now owns 103,109 shares of the medical equipment provider’s stock valued at $1,845,000 after purchasing an additional 20,947 shares during the period. Finally, Signaturefd LLC purchased a new position in BioLife Solutions in the first quarter valued at $161,000. Hedge funds and other institutional investors own 45.76% of the company’s stock.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.